Thursday, January 9, 2014

The Motley Fool: AstraZeneca plc (ADR) Hopes Farxiga Can Go Far

Now the hard work really begins.

AstraZeneca's (NYSE: AZN  ) SGLT-2 inhibitor dapaglifozin has had a difficult path to market, but the company finally got the FDA's go-ahead to market the drug on Wednesday. While SGLT-2 inhibitors are a promising new class of drug, it remains to be seen whether AstraZeneca's Farxiga (it's U.S. brand name) can become a blockbuster in the face of competition from Johnson & Johnson's (NYSE: JNJ  ) first-to-market Invokana and follow-on drugs from Lilly (NYSE: LLY  ) and Astellas.

Please follow this link:
AstraZeneca plc (ADR) Hopes Farxiga Can Go Far

No comments: